Volkswagen Group Diesel Efficiency Foundation (VGDES) and the Consumentenbond Announce that Court Once Again Rules Against Volkswagen in Dutch Dieselgate Proceedings
On Friday October 6, 2023, the Sub-District Court of Oost-Brabant (‘s-Hertogenbosch) ruled that Volkswagen must compensate yet another Dutch Dieselgate consumer who purchased a VW vehicle containing illegal defeat device software. The Court ruled that Volkswagen must pay €4440 - the equivalent of 10% of the vehicle’s purchase price.
This is the latest of four lawsuits brought by the Volkswagen Group Diesel Efficiency Foundation (VGDES) (a Dutch organization representing consumer rights) and Consumentenbond (the Dutch consumer rights organization) on behalf of consumers defrauded by VW. Earlier this year, in March, April and July 2023, other Dutch courts all ruled against Volkswagen finding that it must pay damages to Dutch consumers who similarly purchased vehicles equipped with illegal software. In those prior rulings, the courts awarded €3,000 for an impacted new VW diesel vehicle and €1,500 for a used one. In this latest opinion, the judge increased the penalty finding that those amounts were too low, and determining that the appropriate sanction was a percentage of the vehicle’s purchase price.
A Fourth Defeat for Volkswagen
“This is the fourth time in a row that the Court has ruled against Volkswagen,” said Dick Bouma, chairman of VGDES. “The judge swept aside all VW’s technical legal defenses, and simply found that the car maker deceived consumers. Courts here and all over the world have determined that the company has deliberately misled consumers, including by promoting these diesel cars as environmentally friendly. It is time for Volkswagen to compensate harmed consumers.”
Volkswagen Should Resolve the Claims of the Hundreds of Thousands Dutch Consumers
Sandra Molenaar, Consumentenbond CEO, is pleased with the ruling and looks ahead: “So far we have won all four lawsuits against VW concerning its illegal use of defeat device software in diesel cars. Following this even stronger decision, we again invite Volkswagen to engage in settlement talks. Hopefully, the company is now prepared to compensate all affected Dutch consumers. If not, there are thousands of individual cases we can file against the Company. And, if necessary, we will take each and every case to court to hold Volkswagen accountable and to force the Company to compensate all impacted consumers.”
Links
- March: https://www.consumentenbond.nl/nieuws/2023/doorbraak-in-volkswagen-dieselschandaal-rechter-wijst-compensatie-toe
- April: https://www.consumentenbond.nl/nieuws/2023/weer-succes-in-rechtszaak-om-volkswagen-sjoemeldiesel
- July: https://www.consumentenbond.nl/nieuws/2023/volkswagen-moet-eigenaar-tweedehands-sjoemeldiesel-1500euro-betalen
- October: https://www.consumentenbond.nl/nieuws/2023/volkswagen-opnieuw-veroordeeld-in-dieselgate-procedure
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011132017/en/
Contact information
Source/Contact
Gerard Spierenburg
Consumentenbond
gspierenburg@consumentenbond.nl
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom